Genmab announced changes to its executive committee to support Genmab’s growth and evolution into a fully integrated biotech innovation powerhouse. Genmab’s executive committee will include Rayne Waller in the newly created role of executive VP and chief technology officer and Brad Bailey in the newly created role of executive VP and chief commercial pfficer. Executive VP and COO Anthony Mancini has decided to leave Genmab to pursue other opportunities. Rayne and Brad will report directly to Genmab’s president and CEO Jan van de Winkel and be based in Copenhagen, Denmark and Princeton, New Jersey, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Announces Changes to its Executive Committee
- Genmab A/S Announces Capital Increase Options
- Genmab Announces Capital Boost from Warrants
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Capital Increase in Genmab as a Result of Employee Warrant Exercise